Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Alkermes Plc (ALKS)

Alkermes Plc (ALKS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 5,513,290
  • Shares Outstanding, K 165,118
  • Annual Sales, $ 1,558 M
  • Annual Income, $ 367,070 K
  • EBIT $ 359 M
  • EBITDA $ 387 M
  • 60-Month Beta 0.49
  • Price/Sales 3.42
  • Price/Cash Flow 12.14
  • Price/Book 3.07

Options Overview Details

View History
  • Implied Volatility 54.44% (+1.75%)
  • Historical Volatility 43.49%
  • IV Percentile 53%
  • IV Rank 24.20%
  • IV High 112.83% on 07/17/25
  • IV Low 35.80% on 03/17/25
  • Expected Move (DTE 23) 3.49 (11.23%)
  • Put/Call Vol Ratio 1.93
  • Today's Volume 510
  • Volume Avg (30-Day) 169
  • Put/Call OI Ratio 0.87
  • Today's Open Interest 4,735
  • Open Int (30-Day) 8,193
  • Expected Range 27.56 to 34.53

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 19 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate 0.31
  • Number of Estimates 1
  • High Estimate 0.31
  • Low Estimate 0.31
  • Prior Year 0.92
  • Growth Rate Est. (year over year) -66.30%

Price Performance

See More
Period Period Low Period High Performance
1-Month
30.53 +1.65%
on 02/25/26
35.34 -12.17%
on 02/10/26
-2.57 (-7.65%)
since 01/23/26
3-Month
27.50 +12.87%
on 01/06/26
35.34 -12.17%
on 02/10/26
+2.05 (+7.07%)
since 11/25/25
52-Week
25.17 +23.35%
on 09/08/25
36.32 -14.54%
on 11/05/25
-3.89 (-11.14%)
since 02/25/25

Most Recent Stories

More News
Alkermes: Q4 Earnings Snapshot

Alkermes: Q4 Earnings Snapshot

ALKS : 31.04 (-7.04%)
Alkermes plc Reports Financial Results for the Fourth Quarter and Year Ended Dec. 31, 2025 and Provides Financial Expectations for 2026

Alkermes plc (Nasdaq: ALKS) today reported financial results for the quarter and year ended Dec. 31, 2025 and provided financial expectations for 2026. To view the detailed fourth quarter and full...

ALKS : 31.04 (-7.04%)
Alkermes plc Announces CEO Succession Plan

— Richard Pops to Retire from Role of Chief Executive Officer Following Distinguished 35-year Career with Alkermes — — Board of Directors Appointed Blair Jackson, Alkermes’ Current Executive...

ALKS : 31.04 (-7.04%)
Alkermes to Present at the TD Cowen 46th Annual Health Care Conference

Alkermes plc (Nasdaq: ALKS) announced today that management will participate in a fireside chat at the TD Cowen 46 th Annual Health Care Conference on Monday, March 2, 2026 at 9:10...

ALKS : 31.04 (-7.04%)
Alkermes plc Completes Acquisition of Avadel Pharmaceuticals plc, Accelerating Entry Into Sleep Medicine Market

— Augments Alkermes’ Revenue Growth Profile and Diversifies Commercial Portfolio with New High Potential Growth Product, LUMRYZ ® (Sodium Oxybate) for Extended-Release Oral Suspension...

AVDL : 21.64 (+0.05%)
ALKS : 31.04 (-7.04%)
Alkermes to Report Fourth Quarter and Year-End Financial Results on Feb. 25, 2026

Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET (1:00 p.m. GMT) on Wednesday, Feb. 25, 2026 to discuss the company’s fourth quarter and year-end...

ALKS : 31.04 (-7.04%)
Alixorexton Granted Breakthrough Therapy Designation by U.S. FDA for the Treatment of Narcolepsy Type 1

Alkermes plc (Nasdaq: ALKS) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to alixorexton for the treatment of narcolepsy type 1 (NT1),...

ALKS : 31.04 (-7.04%)
Alkermes to Present at the 44th Annual J.P. Morgan Healthcare Conference

Alkermes plc (Nasdaq: ALKS) announced today that its Chief Executive Officer, Richard Pops, will provide a corporate overview and update at the 44 th Annual J.P. Morgan Healthcare...

ALKS : 31.04 (-7.04%)
Avadel Pharmaceuticals Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Avadel Pharmaceuticals plc - AVDL

NEW YORK and NEW ORLEANS , Dec. 12, 2025 /PRNewswire/ -- Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti , LLC ("KSF") are investigating...

AVDL : 21.64 (+0.05%)
ALKS : 31.04 (-7.04%)
Announcement relating to despatch of Rule 15 proposal

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION....

AVDL : 21.64 (+0.05%)
ALKS : 31.04 (-7.04%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Buy with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

Relative Strength just crossed below 50%. The market is indicating support for a bearish trend.

See More Share

Business Summary

Alkermes plc, formed by the merger of Waltham, MA-based Alkermes, Inc. and Elan Drug Technologies (EDT), is a fully integrated global biopharmaceutical company that utilizes proprietary technologies to research, develop and commercialize, both with partners and on its own pharmaceutical products in major...

See More

Key Turning Points

3rd Resistance Point 34.61
2nd Resistance Point 33.70
1st Resistance Point 32.37
Last Price 31.04
1st Support Level 30.12
2nd Support Level 29.21
3rd Support Level 27.88

See More

52-Week High 36.32
Fibonacci 61.8% 32.06
Last Price 31.04
Fibonacci 50% 30.74
Fibonacci 38.2% 29.43
52-Week Low 25.17

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar